2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Newborn Screening, Omics Technologies, Pathology, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Surgical, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

6093 Comprehensive genomic characterization of circulating multiple myeloma cells by targeted NGS: Comparison with bone marrow FISH

Paola Tononi, PhD, Alberto Ferrarini, PhD2, Marianna Garonzi, PhD3, Federica Sola, PhD4, Giuseppe Giacomo Montefrancesco5, Aliki Ntzifa, PhD6, Eleni Theochari, MS7, Delphine Chabut8, Meletios-Athanasios (Thanos) C. Dimopoulos, MD9, Evi Lianidou10, Efstathios Kastritis, MD11, Nicolò Manaresi, PhD12
1 Menarini Silicon Biosystems SpA, Castel Maggiore, Bologna, Italy
2 Menarini Silicon Biosystems SpA, Castel Maggiore, Bologna, Italy
3 Menarini Silicon Biosystems SpA, Castel Maggiore, Bologna, Italy
4 Menarini Silicon Biosystems SpA, Castel Maggiore, Bologna, Italy
5 Menarini Silicon Biosystems SpA, Castel Maggiore, Bologna, Italy
6 National and Kapodistrian University of Athens, Athens, Greece
7 National and Kapodistrian University of Athens, Athens, Greece
8 Menarini Silicon Biosystems SpA, Castel Maggiore, Bologna, Italy
9 National and Kapodistrian University of Athens, Athens, Greece
10 National and Kapodistrian University of Athens, Athens, Greece
11 National and Kapodistrian University of Athens, Athens, Greece
12 Menarini Silicon Biosystems SpA, Castel Maggiore, Bologna, Italy

Introduction

Multiple myeloma (MM) is a genetically complex and spatially heterogeneous plasma cell malignancy that evolves from asymptomatic precursor conditions, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). Currently, genomic disease characterization and risk stratification rely on invasive bone marrow (BM) aspirates evaluated by fluorescence in situ hybridization (FISH). However, beyond the significant patient burden, BM sampling cannot fully reflect spatial intra-tumor heterogeneity. Furthermore, FISH is limited to a restricted panel of loci and is inherently unable to detect single-nucleotide variants (SNVs) and indels. To overcome these limitations, we present a non-invasive, peripheral blood-based NGS assay enabling targeted genomic characterization of Circulating Multiple Myeloma Cells (CMMCs). This assay allows for the simultaneous detection of IGH translocations, aneuploidies, focal copy number alterations (CNAs), single nucleotide variants (SNVs), and indels across 147 genes, including therapy-induced resistance mutations in T-cell engager targets. 

Methods

Pools ranging from as few as 46 to 300 CMMCs from 73 MM patients (42 at diagnosis, 8 at relapse, 23 at precursor stages), including 63 with matched BM-FISH data at the same timepoint, were sorted after peripheral blood enrichment using the CELLSEARCH® System (overall CMMC counts: 43 - 46,642, median = 690, IQR = 126 - 5,294). Following cell lysis, samples underwent whole-genome DNA library preparation using the DEPArray™ LibPrep kit, followed by targeted enrichment with a custom-designed panel (Twist Bioscience). Sequencing was performed on the Illumina NextSeq 1000 platform, and results were compared with paired BM-FISH data. To evaluate analytical performance in detecting sequence variants, cell pools from 38 patients were orthogonally analyzed using the Ampli1™ OncoSeek panel. 

Results

The assay showed high agreement with FISH, achieving a positive percent agreement (PPA) and positive predictive value (PPV) of 94.4% and 100.0% for translocations, and 94.6% and 93.0% for CNAs, respectively. Notably, the targeted NGS panel identified a focal del(17p) undetected by conventional BM-FISH, suggesting superior resolution for localized genomic events. Furthermore, the panel identified a newly diagnosed MM (NDMM) patient with a hyperhaploid karyotype, characterized by widespread monosomies alongside preserved odd-numbered chromosome disomies, a high-risk genomic profile that may escape detection using standard FISH-based approaches. The NGS panel also exhibited strong concordance with the amplicon-based Ampli1™ OncoSeek panel for variant calling: all 31 variants within shared target regions were co-detected, demonstrating excellent variant allele frequency (VAF) correlation (r = 0.97). Additionally, the NGS panel identified TP53 mutations in six patients; these alterations are inherently undetectable by FISH and are now incorporated into updated high-risk MM definitions. Four of these six mutations occurred as part of double-hit biallelic TP53 events, which severely impact patient prognosis. Importantly, the panel identified genomic loss of key immunotherapy targets, identifying 3 patients with GPRC5D loss and 1 patient with TNFRSF17 (BCMA) loss, highlighting its utility in detecting potential mechanisms of resistance to T-cell redirecting therapies. 

Conclusions 

This novel CMMC-based NGS liquid biopsy assay offers a robust and non-invasive platform for the comprehensive genomic profiling and risk stratification of MM patients. Beyond showing high agreement with BM-FISH, the assay delivers enhanced genomic resolution by detecting SNVs (such as TP53 mutations), focal del(17p), complex ploidy states that may evade standard cytogenetics, and genomic loss of key immunotherapy targets (GPRC5D, TNFRSF17). Altogether, this strategy represents an all-in-one approach for accurate disease characterization and longitudinal monitoring. 

Marianna Garonzi, PhD: Menarini Silicon Biosystems SpA - Current Employment